Combined immunodeficiency-multiple intestinal atresia Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

No FDA or trial events recorded yet for Combined immunodeficiency-multiple intestinal atresia.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Biktarvy

Gilead Sciences, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Biktarvy

(bictegravir, emtricitabine, and tenofovir alafenamide)Orphan drug

Gilead Sciences, Inc.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

12.1 Mechanism of Action BIKTARVY is a fixed dose combination of antiretroviral drugs bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamid...

Approved Jul 2025FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Combined immunodeficiency-multiple intestinal atresia.
Search all trials →

Search clinical trials for Combined immunodeficiency-multiple intestinal atresia →

Recent News & Research

No recent news articles indexed yet for Combined immunodeficiency-multiple intestinal atresia.
Search PubMed for Combined immunodeficiency-multiple intestinal atresia →

Browse all Combined immunodeficiency-multiple intestinal atresia news →

Specialist Network

No specialists currently listed for Combined immunodeficiency-multiple intestinal atresia.

View all Combined immunodeficiency-multiple intestinal atresia specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰